Latest News
-

Important advances in next generation genome editing tools for Huntington's Disease
Work with genome editing techniques (zinc fingers and CRISPR) brings these tools closer to use in HD clinical trials
-

Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
-

EuroBuzz 2016: The Euro-HD Network Meeting in The Hague
All our tweets from #EHDN2016 in one mega-article
-

Ultra-rare mutations highlight the importance of the HD gene in brain development
New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD
-

A support system gone wrong – glial cells contribute to HD symptoms
An elegant new study helps determine how much brain cells called glia matter to HD symptoms
-

Early exposure to the HD protein may cause life-long symptoms
A surprising new mouse study suggests the mutant HD gene may do some of its damage during embryonic development
-

Electron beam snaps best images yet of Huntington's disease protein
Electrons enable huntingtin protein, the cause of Huntington's disease, to be visualised at highest resolution ever
-

Planting trees together: The 2016 Huntington's Disease Society of America Convention
HDBuzz summarizes the science from an unusually large and energized @HDSA convention in Baltimore
-

Huntingtin takes a trip: harmful proteins pass between brain cells
Harmful misfolded huntingtin can travel between brain cells via messenger particles called exosomes
-

Important drug targets yielded by new genetic study of HD
A genetic study confirms that minute differences in DNA repair genes can influence the age of HD symptom onset.
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Previously featured
-
A Second Path: uniQure Plans Regulatory Filing for AMT-130 in the UK
-
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
-
April 2026: This Month in Huntington’s Disease Research
-
The Number on the Scale: What the TFC Score Measures, and Why It Matters Right Now
-
Dancing With a Stranger: Understanding Apathy in Huntington’s Disease Through Caregivers
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
